Dyskinesia News and Research

RSS

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Inc. today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation.

1 Apr 2015

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

Primary ciliary dyskinesia (PCD) is a rare, genetic respiratory tract disorder leading to progressive pulmonary dysfunction. It exhibits many problems typical for orphan diseases: delayed diagnosis, limited evidence-based knowledge etc. The European Union is funding BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) to introduce uniform guidelines for PCD treatment and diagnosis across Europe.

25 Mar 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

NI Research has released the March/April issue of NeuroPerspective, which features comprehensive reviews of two major areas: Schizophrenia and Spinal cord injury.

3 Mar 2015

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Although levodopa remains the "gold standard" to effectively control motor deficits in the treatment of early stage Parkinson's disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment with oral medications for Parkinson's disease, about 40% of patients experience lack of muscle control (dyskinesias), end-of-dose wearing off, and fluctuations in "On/Off" states.

27 Feb 2015

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund University in Sweden seem to be close to a novel therapy to this distressing side effect.

11 Feb 2015

Young Researcher's Meeting on Primary Ciliary Dyskinesia to be held in Bern, Switzerland

Primary ciliary dyskinesia (PCD) is a rare, genetically heterogeneous disorder that affects approximately 1 in 20,000 individuals.

29 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Brandeis University researchers capture highest resolution images of cilia ever

Cilia, the cell's tails and antennas, are among the most important biological structures. They line our windpipe and sweep away all the junk we inhale; they help us see, smell and reproduce. When a mutation disrupts the function or structure of cilia, the effects on the human body are devastating and sometimes lethal.

18 Dec 2014

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia.

30 Oct 2014

Levodopa dose linked to malnutrition risk in Parkinson’s disease

The malnutrition often seen in patients with Parkinson’s disease could be partly an effect of levodopa medication, research suggests.

22 Oct 2014

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

A small freshwater fish found in many tropical aquariums may hold the key to unlocking one of the leading causes of respiratory diseases in humans.

17 Sep 2014

Research to help patients suffering from severe spinal cord injuries

Many patients suffer from severe spinal cord injuries after being involved in traffic accidents or accidents at work.

5 Sep 2014

Study: Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Levodopa is the preferred treatment for Parkinson's disease in the clinic. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the most common, severely affecting patients' quality of life.

5 Aug 2014

Sleep problems in PD patients can worsen in later stages of disease

Up to 70% of Parkinson's disease (PD) patients experience sleep problems that negatively impact their quality of life.

11 Jul 2014

Low accuracy of clinical diagnosis for early Parkinson’s disease

About three-quarters of patients suspected to have early Parkinson’s disease eventually prove to have other conditions, a study shows.

3 Jul 2014

Little efficacy difference between old and new antipsychotics

Older and second-generation long-acting antipsychotics have broadly similar clinical efficacy, shows a randomised trial in JAMA.

21 May 2014

Presynaptic dopaminergic lesion predicts drug-induced dyskinesia

Research suggests that the extent of presynaptic dopaminergic denervation before starting therapy may predict which patients with Parkinson’s disease will later develop levodopa-induced dyskinesia.

19 May 2014

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

6 May 2014

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

29 Apr 2014